A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

Key facts

Sponsor

Stealth BioTherapeutics Inc.

Principal Investigator

Alfredo Sadun, MD, PhD

University of California, Los Angeles

Intervention

elamipretide (MTP-131) 1% topical ophthalmic solution(drug)

Enrollment

12 enrolled

Eligibility

18-50 years · All sexes

Timeline

2016 – 2019

Study locations (1)

• Doheny Eye Center, Pasadena, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hereditary optic neuropathy

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2, PHASE3NCT04912843
  Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy
  Wuhan Neurophth Biotechnology Limited Company

See all trials for Hereditary optic neuropathy →